Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

New dual mTOR/PI3K-alpha inhibitor PF-04979064 may advance to clinic as anticancer agent

Sep. 14, 2010

Vardenafil improves exercise capacity in phase III trial in subjects with PAH

Sep. 14, 2010

New histamine H4 receptor ligand VUF-11488 to be tested in inflammation models

Sep. 13, 2010

Intranasal desmopressin ineffective in relieving renal colic pain

Sep. 13, 2010

INNOVATE-PCI trial data support entry of antiplatelet agent elinogrel in phase III trial

Sep. 13, 2010

Pharmacological profile supports evaluation of GSK-1427400 in chronic pain

Sep. 13, 2010

New gamma-secretase modulators show favorable properties in preclinical evaluation

Sep. 10, 2010

Prodrug delivers fenofibric acid and nitric oxide for cardiovascular disease treatment

Sep. 10, 2010

GSK-2188931 shows promise in rat model of myocardial infarction

Sep. 10, 2010

AGN-196923 alleviates neuropathic pain in animal models

Sep. 10, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.